ESC
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1Â High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2Â Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
The European Society of Cardiology (ESC) has published its first dedicated clinical practice guidelines on cardiac rehabilitation, calling for rehabilitation to be considered a core component of care across a broader range of cardiovascular conditions. Published in the European Heart ...
Prof. Thomas Thum discusses Phase II findings from the HF-REVERT study, what they suggest about patient selection for RNA-based therapies, and how these approaches could offer new ways to treat heart failure.
Prof. Maria Bäck discusses the first dedicated ESC Guidelines on cardiac rehabilitation, why personalization and multidisciplinary care are central to their recommendations, and the importance of increasing referral to rehabilitation programs.
Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.
Dr Jazmin Aguado-Sierra discusses how computational models and digital twins are helping researchers understand different heart failure phenotypes, and how artificial intelligence can accelerate analysis and support more personalized approaches.
Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.
Phase IIb LUMINARA data presented at ESC Congress 2026 suggest that AZD5462 may improve cardiac remodeling and hemodynamics across different heart failure phenotypes, with the lowest dose producing the strongest remodeling signal in HFrEF.
Prof. Jonathan Kalman discusses the rapid uptake of pulsed field ablation, its potential advantages over thermal ablation, and how the role of AF ablation may continue to expand.
Prof. Adriaan Voors discusses the evolving role of GLP-1 receptor agonists in heart failure, the importance of patient selection and monitoring, and how emerging evidence and new guidelines could influence clinical practice.
Dr Bjarne Nes discusses findings from the NEXAF trial, which showed that a one-year exercise program reduced atrial fibrillation burden in patients with non-permanent AF.
AMUNDSEN showed that immediate initiation of evolocumab after myocardial infarction substantially increased LDL-C goal achievement, but did not significantly reduce death or cardiovascular hospitalization at 1 year. Starting evolocumab immediately after myocardial infarction (MI) more than doubled the proportion of patients ...
Prof. George Stergiou discusses wearable, cuffless and screening technologies for blood pressure measurement, where they may add value, and why accuracy remains critical for clinical decision-making.
Phase III SHASTA-3 and SHASTA-4 results showed substantial and sustained triglyceride reductions with plozasiran, alongside fewer acute pancreatitis events.
PRAGUE-26 found that catheter-directed thrombolysis substantially reduced short-term clinical deterioration compared with anticoagulation alone in patients with intermediate–high-risk pulmonary embolism.
Phase III ACACIA-HCM results show significant improvements in symptoms and functional capacity with aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events compared with placebo in the overall CARDIO-TTRansform population, according to late-breaking results presented at ESC Congress 2026 in Munich, Germany.
touchCARDIO
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
